ライフサイエンスコーパス: external-beam radiotherapy

1 greater than when delivered by fractionated external beam radiotherapy.

2 ue radiotherapy are comparable to those from external beam radiotherapy.

3 randomized men to 6 vs 36 months of ADT with external beam radiotherapy.

4 ron (VHEE) beams are an exciting prospect in external beam radiotherapy.

5 with the conventional policy of whole breast external beam radiotherapy.

6 tive radiotherapy and 1119 were allocated to external beam radiotherapy.

7 ed targeted intraoperative radiotherapy plus external beam radiotherapy.

8 ith quality indicators than those undergoing external beam radiotherapy.

9 have shifted towards fractionated conformal external beam radiotherapy.

10 ard treatment doses of both chemotherapy and external beam radiotherapy.

11 ing critical structures, and costs less than external beam radiotherapy.

12 October 31, 1995, and treated initially with external-beam radiotherapy.

13 eceive or not receive postoperative adjuvant external-beam radiotherapy.

14 reatment for neuroblastoma than conventional external-beam radiotherapy.

15 nal risks of BF and PCSD after completion of external-beam radiotherapy.

16 sed prostate cancer is commonly treated with external-beam radiotherapy.

17 data (cell death assay, volume response) and external-beam radiotherapy.

18 data (cell death assay, volume response) and external-beam radiotherapy.

19 ogical effectiveness of 0.4 in comparison to external-beam radiotherapy.

20 ogical effectiveness of 0.4 in comparison to external-beam radiotherapy.

21 patic toxicity similar to 40-Gy fractionated external-beam radiotherapy.

22 ter radical prostatectomy, brachytherapy, or external-beam radiotherapy.

23 adiotherapy, and three-dimensional conformal external-beam radiotherapy.

24 0.4%), plaque radiotherapy (7.0% vs. 5.2%), external beam radiotherapy (1.4% vs. 1.3%), enucleation

25 g of urinary obstruction and irritation with external beam radiotherapy (11.7 [95% CI, 8.7-14.8]) and

26 al prostatectomy (36.2 [95% CI, 30.4-42.0]), external beam radiotherapy (13.9 [95% CI, 6.7-21.2]), an

27 .5%), 469 radical prostatectomy (41.1%), 249 external beam radiotherapy (21.8%), and 109 brachytherap

28 2020, 28 (52%) of 54 countries had access to external beam radiotherapy, 21 (39%) had brachytherapy c

29 5.1-25.9]); and worsened bowel symptoms with external beam radiotherapy (4.9 [95% CI, 2.4-7.4]).

30 operative radiotherapy, 37 [3.3%] of 1113 vs external beam radiotherapy, 44 [3.9%] of 1119; p=0.44).

31 an consisted of 5 weeks of concurrent pelvic external beam radiotherapy (45 Gy) with continuous intra

32 atumoural administration before preoperative external-beam radiotherapy (50 Gy in 25 fractions) or ra

33 l chemotherapy (59% vs. 28%, P = 0.005), and external beam radiotherapy (59% vs. 94%, P < 0.001).

34 External beam radiotherapy (72.7%) was most commonly cho

35 All patients received external-beam radiotherapy according to a strict protoco

36 f 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who u

37 secondary analysis of patients treated with external-beam radiotherapy alone and enrolled in the pro

38 ent, including radical prostatectomy (RP) or external-beam radiotherapy alone, is associated with hig

39 462 (92%) participants received external beam radiotherapy and brachytherapy with a medi

40 ough there is evidence for tumor response to external beam radiotherapy and despite the fact that a r

41 sed prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionatio

42 ment strategies, namely surgery and adjuvant external beam radiotherapy and targeted intraoperative r

43 ll patients to receive evidence-based breast external beam radiotherapy and to facilitate the transla

44 ancer incidence, with 38.4 million requiring external-beam radiotherapy and 28.8 million requiring br

45 We estimated the unique costs of external-beam radiotherapy and brachytherapy and include

46 e health and economic benefits of scaling up external-beam radiotherapy and brachytherapy for cervica

47 rcinoma of the esophagus received concurrent external-beam radiotherapy and chemotherapy followed by

48 on cavities (SCRCs) followed by conventional external-beam radiotherapy and chemotherapy.

49 ave radiosensitizing effects in conventional external-beam radiotherapy and have been tested in clini

50 rovide shorter, more convenient schedules of external-beam radiotherapy and interstitial treatment.

51 rom that of standard whole-breast tangential external-beam radiotherapy and necessitates investigatio

52 y of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachytherapy vs active

53 ss of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile

54 oadjuvant chemotherapy, enucleation, orbital external-beam radiotherapy, and adjuvant chemotherapy.

55 than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term

56 Utilization rates for prostatectomy, external-beam radiotherapy, and observation have fallen

57 Chemoradiotherapy included 45 Gy external beam radiotherapy at 5 fractions per week concu

58 Two patients also received external-beam radiotherapy before IAC.

59 were randomized to receive 70 Gy or 78 Gy of external-beam radiotherapy between 1993 and 1998.

60 ying QoL outcomes for radical prostatectomy, external beam radiotherapy, brachytherapy, and cryothera

61 Treatment with radical prostatectomy, external beam radiotherapy, brachytherapy, or active sur

62 reatment for almost a century, being used in external-beam radiotherapy, brachytherapy, and targeted

63 ry (radical prostatectomy) and radiotherapy (external-beam radiotherapy, brachytherapy, or both) are

64 rostatectomy, or three-dimensional conformal external-beam radiotherapy by a computer-generated alloc

65 w indicated a 15% improvement in the current external beam radiotherapy capacity in Latin America and

66 lerators and, similar to Georgia, high total external beam radiotherapy capacity) than the other ART

67 Conventional external beam radiotherapy (cEBRT) and stereotactic body

68 n reported for in vitro cell cultures or for external-beam radiotherapy clinical studies.

69 Treatment consisted of external beam radiotherapy, concurrent chemotherapy, and

70 External-beam radiotherapy continues to be an important

71 tin 40 mg/m(2) for 5 weeks with 45.0-50.4 Gy external beam radiotherapy delivered in 20-28 fractions

72 weeks, during radiotherapy with 45.0-50.4 Gy external beam radiotherapy delivered in fractions of 1.8

73 py should be considered as an alternative to external beam radiotherapy delivered over several weeks.

74 randomly assigned to receive 60 to 64 Gy of external beam radiotherapy delivered to the prostatic fo

75 , 5-6 cycles, 1 day per cycle, plus 45-50 Gy external-beam radiotherapy delivered in 1.8-2 Gy fractio

76 Neither brachytherapy nor an increase in external beam radiotherapy dose has been proven to impro

77 antageous dose distribution than photons for external beam radiotherapy, due to their so-called inver

78 Radiation therapy (RT) including external beam radiotherapy (EBRT) and internal radioisot

79 atterns for and safety of the combination of external beam radiotherapy (EBRT) and LuPSMA in the real

80 stigate its predictive value for response to external beam radiotherapy (EBRT) and vaginal brachyther

81 Preclinical studies have shown that external beam radiotherapy (EBRT) can synergize with ICI

82 ve radiotherapy (TARGIT) versus fractionated external beam radiotherapy (EBRT) for breast cancer.

83 tudy, we conducted a lifecycle assessment of external beam radiotherapy (EBRT) for ten anatomical dis

84 erapy (ADT) or a brachytherapy boost (BT) to external beam radiotherapy (EBRT) have been shown to imp

85 atic tumor lesion(s) in addition to standard external beam radiotherapy (EBRT) improves biochemical d

86 eing compared with the standard fractionated external beam radiotherapy (EBRT) in randomized trials.

87 the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases

88 of the paclitaxel formulation and dose, but external beam radiotherapy (EBRT) only achieved tumour-g

89 , combining TRT with moderate-dose (12 gray) external beam radiotherapy (EBRT) targeting a single tum

90 External beam radiotherapy (EBRT) was necessary in 33 ey

91 OT1 and NCI-H69 tumor cell lines to PRRT and external beam radiotherapy (EBRT) were compared.

92 Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivat

93 y was to determine in what manner aggressive external beam radiotherapy (EBRT), chemotherapy, surgica

94 Curative-intent radical prostatectomy (RP), external beam radiotherapy (EBRT), or EBRT plus brachyth

95 Patients who underwent external beam radiotherapy (EBRT), radical prostatectomy

96 EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade ly

97 ndividuals with prostate cancer treated with external beam radiotherapy (EBRT).

98 All pts received external beam radiotherapy (EBRT): 45 Gy in 25 fractions

99 Geocoded location of patients receiving external beam radiotherapy (EBRT); median Euclidean dist

100 y (100 microg/delivery) or hyperfractionated external beam radiotherapy (EBRT; 15 Gy total dose).

101 s HT-29 and DLD-1 after exposure to (90)Y or external beam radiotherapy (EBRT; 6 MV photons) were use

102 The combination of external-beam radiotherapy (EBRT) and (177)Lu-labeled pr

103 nt-free survival was defined as avoidance of external-beam radiotherapy (EBRT) and enucleation.

104 sk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy.

105 ment strategy that combines radioiodine with external-beam radiotherapy (EBRT) for patients with low

106 eprivation therapy (ADT) in combination with external-beam radiotherapy (EBRT) in men with locally ad

107 We evaluated the efficacy of external-beam radiotherapy (EBRT) in the palliation of p

108 idene diphosphonate (HEDP) as an adjuvant to external-beam radiotherapy (EBRT) in the treatment of pa

109 Methods: Six cell lines were exposed to external-beam radiotherapy (EBRT) or (177)Lu-DOTATATE, a

110 0; P = .01), low income (OR, 1.74; P < .01), external-beam radiotherapy (EBRT; OR, 0.85; P = .01), an

111 y to calculate current and projected gaps in external beam radiotherapy facilities.

112 Patients then received conventional external-beam radiotherapy followed by a year of alkylat

113 mized clinical trials of patients undergoing external beam radiotherapy for prostate cancer, the cond

114 s and technological advances in image-guided external beam radiotherapy for prostate cancer.

115 TRO) produced an evidence-based guideline on external-beam radiotherapy for patients with locally adv

116 Effects of external-beam radiotherapy for prostate cancer among a p

117 ts who develop an isolated PSA relapse after external-beam radiotherapy for prostate cancer.

118 ctive monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinical

119 rapy group (six patients [0.5%]) than in the external beam radiotherapy group (23 patients [2.1%]; p=

120 ve radiotherapy and 0.95% (0.39-2.31) in the external beam radiotherapy group (difference between gro

121 1025 (92%) patients in the external beam radiotherapy group received the allocated

122 operative radiotherapy group and five in the external beam radiotherapy group.

123 ancers, and combined anti-PD-L1 therapy with external beam radiotherapy has been shown to increase th

124 hemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatm

125 External beam radiotherapy has historically played a min

126 Although external-beam radiotherapy has long integrated dosimetry

127 ormonal ablation therapy in combination with external-beam radiotherapy has shown improvement in prog

128 liable long-term results, and the studies of external-beam radiotherapy have used the best scientific

129 y arms administered before hyperfractionated external-beam radiotherapy (HFEBRT).

130 deprivation has been used as an adjuvant to external beam radiotherapy, however, emerging data sugge

131 ation characteristics, and combinations with external-beam radiotherapy, immunotherapy, and DNA damag

132 radiotherapy (3DCRT) and intensity-modulated external-beam radiotherapy (IMRT), better implant techni

133 omas may be safely managed with fractionated external beam radiotherapy in select patients with possi

134 osting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease

135 The technique of external beam radiotherapy is most often used and is del

136 study indicates that although postoperative external-beam radiotherapy is highly effective in preven

137 rrent solid tumors, for which the utility of external-beam radiotherapy is limited, the prognosis is

138 ently, in metastatic disease, the utility of external-beam radiotherapy is limited.

139 y (n = 3), proton beam radiotherapy (n = 1), external beam radiotherapy (n = 1), systemic chemotherap

140 = 8, 23%), plaque radiotherapy (n = 3, 9%), external beam radiotherapy (n = 1, 3%), cryotherapy (n =

141 or eyelid) metastasis was excision (n = 5), external beam radiotherapy (n = 2), and observation (n =

142 Radical prostatectomy, external beam radiotherapy (n = 359), brachytherapy (n =

143 ents (n = 7), pars-plana vitrectomy (n = 3), external-beam radiotherapy (n = 2), laser (n = 2), and r

144 External-beam radiotherapy of early prostate cancer is f

145 is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer.

146 risk groups for predicting the outcome after external-beam radiotherapy of localized prostate cancer.

147 dle-income countries required treatment with external-beam radiotherapy, of which 7.0 million also re

148 orbed dose-effect relationships adapted from external-beam radiotherapy, often without accounting for

149 rs in up to a third of patients treated with external beam radiotherapy or combined chemoradiotherapy

150 pressive tumor control, without the need for external beam radiotherapy or enucleation.

151 responses to venetoclax combined with either external beam radiotherapy or radioimmunotherapy (RIT),

152 on of ionising radiation (IR) in the form of external beam radiotherapy or targeted radionuclide ther

153 otherapy, hormone therapy, immunotherapy, or external beam radiotherapy or those patients with a soli

154 for tumors recurrent after prior surgery or external beam radiotherapy or unresectable tumors.

155 ate cancer defined by Phoenix criteria after external-beam radiotherapy or brachytherapy as primary t

156 ty-seven and 41 patients had been treated by external-beam radiotherapy or brachytherapy, respectivel

157 erically equivalent to results achieved with external-beam radiotherapy or radical prostatectomy.

158 Standard treatment options include RP, external-beam radiotherapy, or hormonal ablation therapy

159 External-beam radiotherapy plays a critical role in the

160 t screening, and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70

161 t screening, and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70

162 We then assessed the efficacy of external beam radiotherapy plus venetoclax in murine xen

163 In each model, external beam radiotherapy plus venetoclax synergistical

164 treous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic

165 e for 50% (BED50) of 115, 93, and 250 Gy for external-beam radiotherapy, resin microsphere radioembol

166 st in the role of local therapies, including external beam radiotherapy (RT), for men with metastatic

167 y (RP) and up to 45% in patients who receive external beam radiotherapy (RT).

168 rogen deprivation (AD) after initial AD with external-beam radiotherapy (RT) in patients with locally

169 sociated with these treatments compared with external-beam radiotherapy (RT).(1,2).

170 s of androgen deprivation therapy (ADT) with external beam radiotherapy; the EORTC 22961 trial random

171 In external-beam radiotherapy, these tumors present a chall

172 lobular carcinoma) could trigger addition of external beam radiotherapy to targeted intraoperative ra

173 Key exclusion criteria were previous external beam radiotherapy to the target lesion and rece

174 vious treatments included docetaxel (n = 5), external-beam radiotherapy to metastases (n = 5), abirat

175 Cryotherapy, plaque radiotherapy, external beam radiotherapy, tumor removal by partial lam

176 were stratified at randomisation by planned external beam radiotherapy type (intensity-modulated rad

177 Randomisation was stratified by planned external beam radiotherapy type (intensity-modulated rad

178 , bone metastasis, prior chemotherapy, prior external-beam radiotherapy, uptake on the [(111)In-DTPA(

179 th an equivalent absorbed dose delivered via external-beam radiotherapy using tumor volume as a measu

180 Palliative external beam radiotherapy was administered.

181 As of Oct 22, 2022, external beam radiotherapy was available in 32 (78%) of

182 Results: Clonogenic survival after external-beam radiotherapy was cell-line-specific, indic

183 f radiation oncologists believed surgery and external beam radiotherapy were equivalent treatments.

184 y one third of that produced by fractionated external beam radiotherapy, when measured by tumor regro

185 mong men with unfavorable-prognosis disease, external beam radiotherapy with androgen deprivation the

186 Among patients with unfavorable prognosis, external beam radiotherapy with androgen deprivation the

187 , -1.4 [95% CI, -11.1 to 8.3), compared with external beam radiotherapy with androgen deprivation the

188 sease and radical prostatectomy (n = 362) or external beam radiotherapy with androgen deprivation the

189 The patient was treated with ocular external beam radiotherapy with resolution of the intrao

190 stration of tumor progression after standard external-beam radiotherapy with or without chemotherapy

191 intraoperative radiotherapy or whole breast external beam radiotherapy, with blocks stratified by ce

192 U) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of

193 untreated (stratum A), newly diagnosed after external beam radiotherapy (XRT) (stratum B), and recurr

194 ere tested: (a) empty polymer (no drug); (b) external beam radiotherapy (XRT) alone; (c) local chemot

195 Although external beam radiotherapy (xRT) is commonly used to tre